var data={"title":"Microbiology and epidemiology of Cryptococcus neoformans infection","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Microbiology and epidemiology of Cryptococcus neoformans infection</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/contributors\" class=\"contributor contributor_credentials\">Gary M Cox, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/contributors\" class=\"contributor contributor_credentials\">John R Perfect, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 08, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cryptococcosis is an invasive fungal infection due to <em>Cryptococcus neoformans </em>or <em>Cryptococcus gattii</em> that has become increasingly prevalent in immunocompromised patients.</p><p>The microbiology and epidemiology of <em>Cryptococcus</em> species and cryptococcosis will be reviewed here, with an emphasis on <em>C. neoformans</em>. The microbiology and epidemiology of <em>C. gattii</em> is discussed in detail elsewhere. The clinical features, diagnosis, and management of <em>C. neoformans</em> infections are also discussed separately. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis&quot;</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients&quot;</a> and <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a> and <a href=\"topic.htm?path=treatment-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment of Cryptococcus neoformans meningoencephalitis in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=cryptococcus-neoformans-infection-outside-the-central-nervous-system\" class=\"medical medical_review\">&quot;Cryptococcus neoformans infection outside the central nervous system&quot;</a> and <a href=\"topic.htm?path=clinical-management-and-monitoring-during-antifungal-therapy-of-the-hiv-infected-patient-with-cryptococcal-meningoencephalitis\" class=\"medical medical_review\">&quot;Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MICROBIOLOGY</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Taxonomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>C. neoformans</em> and <em>C. gattii</em> are basidiomycetous, encapsulated yeasts. <em>C. neoformans</em> and <em>C. gattii</em> can be subclassified into four serotypes and two species with two varieties. The serotypes are based upon capsular agglutination reactions and are designated A, B, C, or D. </p><p>Serotype A and D cryptococci were previously classified under the species neoformans. However, it has been proposed that the serotype A cryptococci be considered as a separate variety based upon genotypic differences [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/1\" class=\"abstract_t\">1</a>]. Serotype A cryptococci are now considered the variety <em>grubii</em> and are divided into three molecular subtypes: VNI, VNII, and VNB. Serotype D are classified under the variety <em>neoformans</em>. Serotypes B and C are now considered as a separate species called <em>C. gattii</em> [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/2\" class=\"abstract_t\">2</a>]. A detailed discussion of <em>C. gattii</em> is found elsewhere. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis#H3960135\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis&quot;, section on 'Molecular types'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Life cycle</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The life cycle of <em>C. neoformans</em> involves asexual and sexual forms. The asexual form exists as yeast and reproduces by budding. These haploid, unicellular yeasts are the only forms of <em>C. neoformans</em> and <em>C. gattii</em> that have been recovered from human infections.</p><p>The sexual (perfect) state of <em>C. neoformans</em> and <em>C. gattii</em> has been observed only in the laboratory. Sexual structures have not been found in nature, but apparent sexual recombination events have been detected [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/3\" class=\"abstract_t\">3</a>]. The yeast forms can exist in one of two mating types designated a and alpha. Coculture of yeast of each mating type on certain agars can result in conjugation that produces the sexual state. Conjugation between the alpha and a types results in the formation of the teleomorph, which consists of dikaryotic hyphae that contain clamp connections.</p><p>Some of the hyphae develop into specialized structures called basidia. Meiosis occurs at the terminal portion of the basidia resulting in formation of uninucleate basidiospores. These spores are initially unencapsulated but can quickly develop capsules when released from the basidia. Budding may begin after encapsulation, thereby completing the life cycle.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Growth and identification</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>C. neoformans</em> and <em>C. gattii</em> produce white mucoid colonies on a variety of agars that usually become visible to the naked eye within 48 hours (<a href=\"image.htm?imageKey=ID%2F75483\" class=\"graphic graphic_picture graphicRef75483 \">picture 1</a>). The identification of <em>C. neoformans</em> and <em>C. gattii</em> in the clinical laboratory begins with isolation of a urease-positive, encapsulated yeast. Further confirmation can be achieved with biochemical tests contained in commercial kits and by detection of the enzyme phenol oxidase, which is solely produced by <em>C. neoformans</em> and <em>C. gattii</em>. However, most clinical microbiology laboratories do not stock the expensive agars required for detecting this enzyme. Most laboratories use a variety of sugar fermentations contained in commercial kits to identify the organism. However, it is likely that in the future these species will be rapidly and efficiently identified by matrix-assisted laser desorption ionization&ndash;time of flight mass spectrometry (MALDI-TOF) in the clinical laboratory [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/4\" class=\"abstract_t\">4</a>].</p><p><em>C. neoformans</em> can be distinguished from <em>C. gattii</em> by growth features on canavanine-glycine-bromothymol blue (CGB) agar or by molecular tests. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis#H12417218\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;, section on 'Culture and histopathology'</a> and <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis#H12417232\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;, section on 'Molecular tests'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Histologic identification</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The yeast form of <em>Cryptococcus</em> can be identified in histopathologic specimens using methenamine silver stain. Mucicarmine stain highlights both the yeast form and the capsule and is specific for <em>Cryptococcus</em> (<a href=\"image.htm?imageKey=ID%2F82930\" class=\"graphic graphic_picture graphicRef82930 \">picture 2</a>). The Fontana-Masson stain reveals melanin contained in the yeast.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Capsule</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The polysaccharide capsule surrounding <em>C. neoformans</em> and <em>C. gattii</em> can be visualized in a suspension of India ink when examined under the microscope. The capsule appears as a clear area amidst the ink particles (<a href=\"image.htm?imageKey=ID%2F63752\" class=\"graphic graphic_picture graphicRef63752 \">picture 3</a>). The thickness of the capsule can vary but can comprise more than 50 percent of the diameter of the yeast cell in some isolates.</p><p>The capsule has antiphagocytic properties and is an important virulence determinant [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/5\" class=\"abstract_t\">5</a>]. Mutant cryptococci that are either hypocapsular or acapsular are less virulent in animal models than encapsulated strains and undergo increased phagocytosis by white blood cells in vitro [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p><em>C. neoformans</em> and <em>C. gattii</em> strains can undergo phenotypic switching with prolonged in vitro passage, and one group has demonstrated this phenomenon in vivo in mice, resulting in increased virulence and death [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/8\" class=\"abstract_t\">8</a>]. In this model, phenotypic switching led to changes in the polysaccharide capsule, which further reduced alveolar macrophage phagocytosis and promoted a more vigorous inflammatory reaction that was destructive to lung tissue.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Melanin production</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presence of the enzyme phenol oxidase in <em>C. neoformans</em> is unique among members of the genus. This enzyme catalyzes one step in the conversion of phenolic compounds to melanin. A wide variety of phenolic substrates can be utilized by the cryptococcal phenol oxidase, including catecholamines, such as dopamine and epinephrine.</p><p>The phenol oxidase enzyme may be an important virulence factor for cryptococcal infection. Cryptococcal mutants lacking phenol oxidase activity are avirulent in animal models and are more susceptible to antibody-mediated phagocytosis [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Phenol oxidase may promote virulence via one of several possible mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High level of dopamine in the central nervous system may serve as a substrate for melanin production by the organism [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/10\" class=\"abstract_t\">10</a>]. In addition, the ability to degrade catecholamines may protect the yeast from toxic effects of catecholamines in the central nervous system [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/11\" class=\"abstract_t\">11</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Melanin is an antioxidant that is produced and accumulates in the cell wall where it may protect against attack by immune effector cells and oxidative products [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">ECOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Significant differences in the ecology of the two species of <em>Cryptococcus</em> account for the distribution of infections due to these organisms.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">C. neoformans var grubii and var neoformans</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>C. neoformans</em> var <em>grubii</em> and var <em>neoformans</em> have been found in soil samples from around the world in areas frequented by birds, especially pigeons and chickens [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/13\" class=\"abstract_t\">13</a>]. This fungus has also been isolated from roosting sites of pigeons and in association with rotting vegetation [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/14\" class=\"abstract_t\">14</a>].</p><p>The basis for the association of pigeons with <em>C. neoformans</em> var <em>neoformans</em> is uncertain. Pigeons do not become infected with <em>C. neoformans</em> in nature. The organism is probably inhibited within pigeons by their elevated body temperature (over 40&ordm;C). Pigeons can, however, harbor the yeast as saprophytes in their gastrointestinal tract.</p><p>The role of pigeon guano in the pathogenesis of human infections is obscure. A history of intense pigeon exposure is only rarely elicited from patients with cryptococcosis. In addition, outbreaks of the disease have never been traced to pigeon roosting areas. It is possible that pigeons come into contact with <em>C. neoformans</em> var <em>grubii</em> and var <em>neoformans</em> by eating contaminated vegetation. Human infection may result from a similar exposure to contaminated vegetation.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">C. gattii</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The ecology of <em>C. gattii</em> is discussed in detail separately. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis#H43972912\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis&quot;, section on 'Environmental exposure'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cryptococcosis occurs worldwide. The vast majority of patients with cryptococcosis are immunocompromised due to one of the following conditions (listed in order of decreasing frequency):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>AIDS</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolonged treatment with glucocorticoids</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Organ transplantation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignancy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver disease [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/15\" class=\"abstract_t\">15</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sarcoidosis [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/16\" class=\"abstract_t\">16</a>]</p><p/><p>An incidence of 4.9 cases of cryptococcosis per 100,000 population was found in both San Francisco and Atlanta in 1992 [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/17\" class=\"abstract_t\">17</a>]. Underlying AIDS and African-American race were independently associated with cryptococcal infection in these cities. Cryptococcal infection is the fourth most common opportunistic infection in patients with AIDS [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/18,19\" class=\"abstract_t\">18,19</a>]. Approximately 6 to 10 percent of patients with AIDS in the pre&ndash;highly active antiretroviral therapy (HAART) era in the United States and Europe were diagnosed with cryptococcosis. The number of cryptococcosis cases has declined since the availability of HAART [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/20\" class=\"abstract_t\">20</a>], but this infection is still a relatively common AIDS-presenting illness. The rate of cryptococcal meningitis in patients with AIDS in sub-Saharan Africa is 15 to 30 percent [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/19\" class=\"abstract_t\">19</a>]. In fact, it has been estimated that there are approximately one million new cases of cryptococcosis worldwide each year, with over 600,000 deaths [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Some HIV-negative patients with cryptococcal meningitis have been described who had anti-granulocyte macrophage colony stimulating factor (GM-CSF) autoantibodies and later developed pulmonary alveolar proteinosis [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/22\" class=\"abstract_t\">22</a>]. A later study found an association between anti&ndash;GM-CSF autoantibodies and central nervous system <em>C. gattii</em> infection [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/23\" class=\"abstract_t\">23</a>]. GM-CSF regulates the function of phagocytes and pulmonary alveolar macrophages, which are important for control of <em>Cryptococcus </em>[<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/22\" class=\"abstract_t\">22</a>]. </p><p>As noted above, despite the finding of this fungus in pigeon guano, direct transmission from pigeons to humans has not been reported. However, one case has been documented of transmission of <em>C. neoformans </em>from a pet cockatoo to a renal transplant recipient who developed cryptococcal meningitis [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/24\" class=\"abstract_t\">24</a>]. Spread of infection from person to person has not been documented. Interestingly, cryptococcosis is very uncommon in children, even those with AIDS. The reason for the reduced incidence in children is not known.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Pathogenic species</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>C. neoformans </em>is the principal pathogenic member of the genus and has a worldwide distribution. The serotypes or genotypes of <em>C. neoformans</em> in cases of cryptococcosis vary according to geographic location and whether the patient has HIV infection as a predisposing condition.</p><p>An extensive review of 725 clinical isolates of <em>C. neoformans </em>obtained from around the world prior to the AIDS epidemic found that <em>C. neoformans </em>var <em>grubii </em>and <em>C. neoformans </em>var <em>neoformans </em>accounted for 80 percent of isolates [<a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/25\" class=\"abstract_t\">25</a>]. The majority of cryptococcal isolates from patients with AIDS have been <em>C. neoformans </em>var <em>grubii</em> but, in certain locales, <em>C. gattii</em> infections have been observed in HIV-infected patients. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis#H3960149\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis&quot;, section on 'Hosts'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cryptococcosis is an invasive fungal infection that has become increasingly prevalent in immunocompromised patients and is a major pathogen worldwide. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Cryptococcus neoformans</em> and <em>Cryptococcus gattii </em>are basidiomycetous, encapsulated yeasts. <em>C. neoformans</em> can be subclassified in two varieties (var <em>grubii</em> and var <em>neoformans</em>). (See <a href=\"#H3\" class=\"local\">'Taxonomy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The life cycles of <em>C. neoformans</em> and <em>C. gattii</em> involve asexual and sexual forms. The asexual forms exist as yeasts and reproduce by budding. These haploid, unicellular yeasts are the only forms of <em>C. neoformans</em> and <em>C. gattii </em>that have been recovered from human infections. (See <a href=\"#H4\" class=\"local\">'Life cycle'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>C. neoformans </em>var <em>grubii </em>and var <em>neoformans </em>have been found in soil samples from around the world in areas frequented by birds, especially pigeons and chickens, and in association with rotting vegetation. (See <a href=\"#H10\" class=\"local\">'C. neoformans var grubii and var neoformans'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cryptococcosis occurs worldwide. The vast majority of patients with cryptococcosis are immunocompromised due to one of the following conditions (listed in order of decreasing frequency): AIDS, prolonged treatment with glucocorticoids, organ transplantation, malignancy, liver disease, and sarcoidosis. (See <a href=\"#H12\" class=\"local\">'Epidemiology'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/1\" class=\"nounderline abstract_t\">Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999; 37:838.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/2\" class=\"nounderline abstract_t\">Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 2015; 78:16.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/3\" class=\"nounderline abstract_t\">Saul N, Krockenberger M, Carter D. Evidence of recombination in mixed-mating-type and alpha-only populations of Cryptococcus gattii sourced from single eucalyptus tree hollows. Eukaryot Cell 2008; 7:727.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/4\" class=\"nounderline abstract_t\">Firacative C, Trilles L, Meyer W. MALDI-TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex. PLoS One 2012; 7:e37566.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/5\" class=\"nounderline abstract_t\">Eisenman HC, Casadevall A, McClelland EE. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep 2007; 9:457.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/6\" class=\"nounderline abstract_t\">Kozel TR, Gotschlich EC. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 1982; 129:1675.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/7\" class=\"nounderline abstract_t\">Chang YC, Penoyer LA, Kwon-Chung KJ. The second capsule gene of cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 1996; 64:1977.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/8\" class=\"nounderline abstract_t\">Fries BC, Taborda CP, Serfass E, Casadevall A. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest 2001; 108:1639.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/9\" class=\"nounderline abstract_t\">Salas SD, Bennett JE, Kwon-Chung KJ, et al. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med 1996; 184:377.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/10\" class=\"nounderline abstract_t\">Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986; 51:218.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/11\" class=\"nounderline abstract_t\">Polacheck I, Platt Y, Aronovitch J. Catecholamines and virulence of Cryptococcus neoformans. Infect Immun 1990; 58:2919.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/12\" class=\"nounderline abstract_t\">Wang Y, Aisen P, Casadevall A. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun 1995; 63:3131.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/13\" class=\"nounderline abstract_t\">EMMONS CW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 1955; 62:227.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/14\" class=\"nounderline abstract_t\">Laz&eacute;ra MS, Pires FD, Camillo-Coura L, et al. Natural habitat of Cryptococcus neoformans var. neoformans in decaying wood forming hollows in living trees. J Med Vet Mycol 1996; 34:127.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/15\" class=\"nounderline abstract_t\">Spec A, Raval K, Powderly WG. End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis. Open Forum Infect Dis 2016; 3:ofv197.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/16\" class=\"nounderline abstract_t\">Bernard C, Maucort-Boulch D, Varron L, et al. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. QJM 2013; 106:523.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/17\" class=\"nounderline abstract_t\">Hajjeh RA, Brandt ME, Pinner RW. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol Rev 1995; 17:303.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/18\" class=\"nounderline abstract_t\">Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:533.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/19\" class=\"nounderline abstract_t\">Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17:837.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/20\" class=\"nounderline abstract_t\">Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/21\" class=\"nounderline abstract_t\">Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/22\" class=\"nounderline abstract_t\">Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 2013; 190:3959.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/23\" class=\"nounderline abstract_t\">Saijo T, Chen J, Chen SC, et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. MBio 2014; 5:e00912.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/24\" class=\"nounderline abstract_t\">Nosanchuk JD, Shoham S, Fries BC, et al. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000; 132:205.</a></li><li><a href=\"https://www.uptodate.com/contents/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection/abstract/25\" class=\"nounderline abstract_t\">Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984; 120:123.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2448 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MICROBIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Taxonomy</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Life cycle</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Growth and identification</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Histologic identification</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Capsule</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Melanin production</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">ECOLOGY</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">C. neoformans var grubii and var neoformans</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">C. gattii</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">EPIDEMIOLOGY</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Pathogenic species</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2448|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/75483\" class=\"graphic graphic_picture\">- Cryptococcus neoformans Sabouraud agar</a></li><li><a href=\"image.htm?imageKey=ID/82930\" class=\"graphic graphic_picture\">- Cryptococcus lung histopathology</a></li><li><a href=\"image.htm?imageKey=ID/63752\" class=\"graphic graphic_picture\">- Cryptococcus neoformans India ink</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-management-and-monitoring-during-antifungal-therapy-of-the-hiv-infected-patient-with-cryptococcal-meningoencephalitis\" class=\"medical medical_review\">Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">Cryptococcus gattii infection: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis\" class=\"medical medical_review\">Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-neoformans-infection-outside-the-central-nervous-system\" class=\"medical medical_review\">Cryptococcus neoformans infection outside the central nervous system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment of Cryptococcus neoformans meningoencephalitis in HIV-infected patients</a></li></ul></div></div>","javascript":null}